| Bioactivity | FTISADTSK-13C6,15N2 TFA is 13C- and 15N-labeled FTISADTSK (HY-P3146). FTISADTSK is an endogenous stable signature peptide from Trastuzumab monitored by selected reaction monitoring (SRM)[1][2]. |
| Invitro | 氢、碳和其他元素的稳定重同位素已被纳入药物分子中，主要作为药物开发过程中定量的示踪剂。氘化引起了人们的关注，因为它可能影响药物的药代动力学和代谢谱[1]。 |
| Name | FTISADTSK-13C6,15N2 (TFA) |
| Formula | C3813C6H69F3N815N2O18 |
| Molar Mass | 1091.01 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. |
FTISADTSK-13C6,15N2 (TFA)
CAS: F: C3813C6H69F3N815N2O18 W: 1091.01
FTISADTSK-13C6,15N2 TFA is 13C- and 15N-labeled FTISADTSK (HY-P3146). FTISADTSK is an endogenous stable signature peptid
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.